About
Synthetic Lethal Therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalBoston & New England
Team (15)
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
7
As Collaborator
3
Total Enrollment
1,113
By Phase
PHASE1: 5PHASE2: 1PHASE1/PHASE2: 4
By Status
ACTIVE_NOT_RECRUITING: 4TERMINATED: 3RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06560632Lead Sponsor
Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
PHASE1Active, not recruiting
26 participants
Started: Sep 17, 2024 · Completed: Dec 31, 2028
NCT06232408Lead Sponsor
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
PHASE1Active, not recruiting
29 participants
Started: Feb 14, 2024 · Completed: Oct 31, 2025
NCT05605509Collaborator
RP-6306 in Patients With Advanced Cancer
PHASE2Active, not recruiting
28 participants
Started: May 24, 2023 · Completed: May 31, 2026
NCT05566574Collaborator
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
PHASE1/PHASE2Recruiting
84 participants
Started: Sep 30, 2022 · Completed: Sep 30, 2025
NCT05405309Collaborator
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
PHASE1/PHASE2Terminated
5 participants
Started: Sep 23, 2022 · Completed: Jan 10, 2025
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...